GO
Loading...

Sanofi SA

More

  • LONDON, Sept 25- European shares slipped to a one-month low in late trading on Thursday, tracking a sell-off in U.S. stocks, as a stronger dollar undercut prices for industrial metals, causing mining shares to drop.

  • European shares fall in late sell-off, miners slip Thursday, 25 Sep 2014 | 11:23 AM ET

    *FTSE 100 underperforms on concerns of rate hike. The STOXX Europe 600 Basic Resources index fell 2.1 percent to feature as the biggest sectoral decliner in Europe after prices of key base metals fell following a rise in the dollar index, which measures the greenback against a basket of major currencies, to a four-year high.

  • NEW YORK, Sept 25- MannKind Corp shares were among the most actively traded in premarket on Thursday, after the company said it had closed a licensing agreement with Sanofi for the development and commercialization of its inhaled insulin product. MannKind said it will receive a $150 million upfront payment within 10 days of the closing.

  • European shares up, weaker euro seen boosting earnings Thursday, 25 Sep 2014 | 7:18 AM ET

    *Telecom Italia up on report businessman seeks finance for bid. LONDON, Sept 25- European shares extended the previous session's rebound on Thursday as a further drop in the euro fuelled expectations of a boost to the region's corporate earnings. Federal Reserve and the European Central Bank.

  • European shares inch higher as euro falls further Thursday, 25 Sep 2014 | 4:09 AM ET

    PARIS, Sept 25- European shares gained ground in early trade on Thursday, extending the previous session's rebound as a further drop in the euro fuelled expectations of a boost to the region's corporate earnings. Federal Reserve and the European Central Bank.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • Sept 18- An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the U.S. Food and Drug Administration.

  • Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

  • Sept 11- Ebola is just one of many neglected tropical diseases that badly need attention. The World Health Organization in 2012 designated 17 diseases as priorities for eradication or control:. There is no approved drug but the first vaccine from Sanofi could reach the market late next year.

  • The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.

  • Long-awaited diet pill gets U.S. approval Wednesday, 10 Sep 2014 | 9:00 PM ET

    Sept 10- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

  • Sept 10- Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus. The therapy received a positive recommendation from the European Medicine Agency in June.

  • Sept 5- Keryx Biopharmaceuticals Inc won U.S. approval for its drug to lower phosphate levels in patients with chronic kidney disease, but the approval included an unexpected safety warning on the label. However, the FDA- mandated label does not include the benefits of the drug in treating anemia.

  • Keryx Biopharma gets U.S. approval for kidney drug Friday, 5 Sep 2014 | 11:28 AM ET

    Sept 5- Keryx Biopharmaceuticals Inc won the U.S. Food and Drug Administration approval for its drug to lower phosphate levels in patients with chronic kidney disease who are already on dialysis. It affects more than 20 million adults in the United States, according to the U.S. Centers for Disease Control and Prevention.

  • *10 cents move in euro: 1 bln euro swing in Airbus's op profits. *Airbus, Sanofi, Luxottica seen among big winners.

  • PARIS, Sept 3- French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros in the project, undertaking two decades of research on the world's fastest-growing tropical disease.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *Sanofi, Regeneron vying with drugs from Amgen and Pfizer. BARCELONA, Aug 31- An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.